Key regions: United States, Europe, Brazil, Japan, United Kingdom
Bronchodilator drugs, which are used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), are in high demand in Madagascar.
Customer preferences: The demand for bronchodilator drugs in Madagascar is driven by the high prevalence of respiratory diseases in the country, which is largely due to air pollution, smoking, and poor living conditions. Patients in Madagascar prefer bronchodilator drugs that are affordable, effective, and easy to use.
Trends in the market: In recent years, there has been a growing trend towards the use of combination therapies, which involve the use of multiple bronchodilator drugs in a single inhaler. This trend is driven by the fact that combination therapies are more effective at treating respiratory diseases than single bronchodilator drugs. Another trend in the market is the increasing use of generic bronchodilator drugs, which are more affordable than branded drugs.
Local special circumstances: Madagascar is a low-income country with limited healthcare resources. As a result, many patients in the country cannot afford expensive branded bronchodilator drugs. This has led to a high demand for generic drugs, which are more affordable. In addition, the lack of healthcare infrastructure in the country means that many patients are unable to access healthcare services, including respiratory specialists. This has led to a high demand for over-the-counter bronchodilator drugs, which can be purchased without a prescription.
Underlying macroeconomic factors: Madagascar is one of the poorest countries in the world, with a GDP per capita of less than $500. The country's economy is largely dependent on agriculture, which accounts for more than 25% of GDP. The low income levels in the country mean that many patients cannot afford expensive branded bronchodilator drugs. In addition, the lack of healthcare infrastructure in the country means that many patients are unable to access healthcare services, including respiratory specialists. This has led to a high demand for over-the-counter bronchodilator drugs, which can be purchased without a prescription.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
